Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Haemophilia Walk-a-Thon

    - PMLiVE

    SAY Communications teams up with Overcoming MS, a multiple sclerosis charity

    The MS charity is this year’s recipient of the company’s pro bono programme

    - PMLiVE

    Novo Nordisk’s Alhemo approved by FDA for expanded haemophilia use

    The rare bleeding disorder affects approximately 800,000 people globally

    - PMLiVE

    Pfizer shares positive phase 3 results for haemophilia A and B therapy Hympavzi

    Around 20% and 3% of haemophilia A and B patients, respectively, develop inhibitors

    - PMLiVE

    The outlook for healthcare comms in 2025

    By Lorraine Walters and Melissa Kerschen

    - PMLiVE

    Pfizer’s Hympavzi granted MHRA approval to treat haemophilia A and B

    More than 11,800 people were living with the genetic blood disorders in the UK in 2023/2024

    - PMLiVE

    Novo Nordisk’s haemophilia A therapy Mim8 shows promise in late-stage study

    The inherited bleeding disorder accounts for up to 85% of the 1,125,000 global haemophilia cases

    - PMLiVE

    Novo Nordisk invests $1.2bn to establish rare disease production facility in Denmark

    The site will be designed to accommodate multiple product types within rare diseases

    - PMLiVE

    Pfizer’s Hympavzi receives EC approval to treat haemophilia A and B patients

    The genetic blood disorder affects more than 800,000 people globally

    - PMLiVE

    Novo Nordisk’s Alhemo recommended by CHMP for haemophilia A and B

    The rare bleeding disorder affects approximately 1,125,000 people globally

    - PMLiVE

    Pfizer’s Hympavzi granted FDA approval to treat haemophilia in adult and paediatric patients

    More than 800,000 people globally are affected by the genetic blood disorder

    - PMLiVE

    Engaging with HCPs – are you optimising your remote and in-person communications?

    By Lorraine Walters

    - PMLiVE

    Positive results for Sanofi’s haemophilia therapy published in The Lancet

    Fitusiran reduced annualised bleeding rates by 90% compared to control arms

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links